ArticleJournal of fluorescence2026
Ratiometric Fluorescent Sensing of MMP-3 via FRET for Postoperative Rehabilitation Assessment and Prognostic Monitoring Following Joint Surgery.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinase-3 (MMP-3) is a critical biomarker for inflammatory responses and tissue remodeling following joint surgery. Here, we developed a ratiometric fluorescence probe based on fluorescence resonance energy transfer (FRET) for sensitive and selective detection of MMP-3 activity. The probe comprises CdTe quantum dots (R-QDs) as the energy donor and BHQ as the acceptor, linked by an MMP-3-cleavable peptide. Upon MMP-3 cleavage, the FRET process is disrupted, resulting in fluorescence recovery at 540 nm, while the reference signal at 690 nm remains constant, enabling ratiometric quantification. The probe exhibits a linear response from 20 to 100 nM with a detection limit of 7.8 nM and excellent selectivity against other MMPs and interfering proteins. Clinical validation using serum samples from 11 subjects (5 healthy controls and 6 post-surgery patients) successfully distinguished patients from controls. Moreover, real-time monitoring of 6 patients over 18 days post-surgery revealed a clear correlation between MMP-3 levels and rehabilitation progress. These results demonstrate that our ratiometric FRET probe holds promise for postoperative rehabilitation assessment and prognostic monitoring following joint surgery.
Indexed as
Identifiers
42786266What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.